{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-057008","form_type":"8-K","ticker":"SPRB","cik":"0001683553","company_name":"SPRUCE BIOSCIENCES, INC.","filed_at":"2021-11-15T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.670207+00:00","generated_at":"2026-06-28T08:28:35.367231+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Spruce Q3 net loss $11.4M; CAHmelia-203 topline delayed to 2023; CEO retired","bullets":["Net loss of $11.4M for Q3 2021; cash and investments $131.3M as of Sep 30.","R&D expenses $8.6M (Q3 2021) vs $7.8M (Q3 2020); G&A $2.8M vs $1.8M.","CAHmelia-203 topline results now expected in 2023 due to COVID-19 enrollment impact.","Phase 2 trials in pediatric CAH and PCOS remain on track for initiation.","CEO Richard King retired; Executive Chairman Mike Grey appointed Interim CEO."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-057008","json":"https://secwatch.observer/filing/0001564590-21-057008.json","markdown":"https://secwatch.observer/filing/0001564590-21-057008.md","text":"https://secwatch.observer/filing/0001564590-21-057008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1683553/000156459021057008/0001564590-21-057008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1683553/000156459021057008/sprb-8k_20211115.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T08:28:35.367231+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}